摘要
目的：检测并分析HER－2／neu在新辅助化疗乳腺癌组织中的表达，探讨新辅助化疗患者中HER－2／neu的临床意义。方法：采用免疫组织化学法分别检测HER－2／neu在165例新辅助化疗及73例未化疗乳腺癌组织中的表达状况，统计分析HER－2／neu表达与化疗、病理类型及腋淋巴结转移情况的关系。结果：新辅助化疗组HER－2／neu表达低于未化疗组（29．7％比43．8％，P＜0．05）；浸润性非特殊型乳腺癌HER－2／neu阳性表达明显高于浸润性特殊型（粘液腺癌0／4），但浸润性非特殊型乳腺癌之间HER－2／neu表达差异无显著性意义；腋淋巴结转移组HER－2／neu表达明显高于腋淋巴结阴性组（40．1％比25．0％，P＜0．05）。结论：HER－2／neu可能成为在新辅助化疗乳腺癌患者优于淋巴结状况的一个评价肿瘤生物学行为、预测治疗效果指导综合治疗方案制定以及判断预后的重要标志。
Objective To study the clinical significance of overexpression of HER－2／neu in breast cancer following neoadjuvant chemotherapy． Methods The expression of HER－2／neu in 165 cases treated with neoadjuvant chemotherapy and another 73 cases treated with only operation were examined by immunohistochemistry and analysed． Results The HER－2／neu expression in neoadjuvant chemotherapy group was lower than that of operation only group 29．7％ vs 43．8％ respectively P＜0．05． HER－2／neu expression is lower in infiltrative specific breast carcinoma mucinous adenocarcinoma 0／4 than that in infiltrative non－specific breast carcinoma infiltrative ductal carcinoma 31．9％ carcinoma simplex 38．5％ medullary carcinoma 40．0％． The difference among infiltrative non－specific breast cancer was not significant． The HER－2／neu expression in lymph node metastatic cases was higher than that without lymph node metastasis cases 40．1％ vs 25．0％ respectively P＜0．05． Conclusion HER－2／neu seems to be a useful tumor marker in patients treated with neoadjuvant chemotherapy． It can be used to evaluate tumor biological behavior and predict the sensitivity of treatment and as a prognostic factor it is superior to the lymph node status in neoadjuvant chemotherapy patients．
出处
《中国肿瘤临床》
CAS
CSCD
北大核心
2001年第7期508-510,共3页
Chinese Journal of Clinical Oncology
